Taysha Gene Therapies Files 8-K on Financials
Ticker: TSHA · Form: 8-K · Filed: Aug 12, 2025 · CIK: 1806310
Sentiment: neutral
Topics: financial-condition, results-of-operations, filing
TL;DR
Taysha Gene Therapies dropped an 8-K on Aug 12th covering financials. Check it out.
AI Summary
Taysha Gene Therapies, Inc. filed an 8-K on August 12, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with the company's principal executive offices located at 3000 Pegasus Park Drive, Suite 1430, Dallas, Texas.
Why It Matters
This filing provides an update on Taysha Gene Therapies' financial performance and condition, which is crucial for investors to assess the company's stability and future prospects.
Risk Assessment
Risk Level: low — This is a routine filing of financial information and does not indicate any immediate material changes or risks.
Key Players & Entities
- Taysha Gene Therapies, Inc. (company) — Registrant
- August 12, 2025 (date) — Date of earliest event reported
- 3000 Pegasus Park Drive, Suite 1430, Dallas, Texas 75247 (address) — Principal Executive Offices
- 001-39536 (company_id) — SEC File Number
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Taysha Gene Therapies, Inc.'s results of operations and financial condition, and to include financial statements and exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on August 12, 2025.
Where are Taysha Gene Therapies, Inc.'s principal executive offices located?
Taysha Gene Therapies, Inc.'s principal executive offices are located at 3000 Pegasus Park Drive, Suite 1430, Dallas, Texas 75247.
What is the SEC file number for Taysha Gene Therapies, Inc.?
The SEC file number for Taysha Gene Therapies, Inc. is 001-39536.
What is the SIC code for Taysha Gene Therapies, Inc.?
The Standard Industrial Classification (SIC) code for Taysha Gene Therapies, Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Stats: 530 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2025-08-12 08:10:37
Key Financial Figures
- $0.00001 — nge on which registered Common Stock, $0.00001 par value TSHA The Nasdaq Stock Mar
Filing Documents
- d51118d8k.htm (8-K) — 26KB
- d51118dex991.htm (EX-99.1) — 85KB
- 0001193125-25-178504.txt ( ) — 239KB
- tsha-20250812.xsd (EX-101.SCH) — 3KB
- tsha-20250812_lab.xml (EX-101.LAB) — 18KB
- tsha-20250812_pre.xml (EX-101.PRE) — 11KB
- d51118d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated August 12, 2025. 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Taysha Gene Therapies, Inc. Dated: August 12, 2025 By: /s/ Kamran Alam Kamran Alam Chief Financial Officer